晚期肠癌靶向治疗进展徐瑞华教授.pptVIP

晚期肠癌靶向治疗进展 徐瑞华 MD PhD 中山大学肿瘤医院内科 xurh@mail.sysu.edu.cn 主要内容 以分子指标为指导的靶向治疗时代的来临 多个靶向药物联合的重新定位 靶向药物治疗的广泛研究 ERBITUX in first-line treatment of mCRC Phase III CRYSTAL study: Study design Stratification factors: Region ECOG performance status Populations: Randomized patients (n=1217) Safety population (n=1202) ITT population (n=1198) Primary endpoint: PFS (ITT population) Independent assessment of response KRAS analysis: Objective and methodology To retrospectively investigate the impact of the KRAS mutation status of tumors on PFS and RR in the first-line treatment of mCRC with FOLFIRI ± ERBIT